Gemphire Therapeutics Inc. (NASDAQ: GEMP) Attends 31st Annual ROTH Conference
Gemphire Therapeutics (NASDAQ: GEMP) is a clinical-stage biopharmaceutical company committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins that will benefit patients, physicians, and payors. Gemphire’s phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, hypertriglyceridemia, and fatty liver disease, including FH, SHTG, NASH/NAFLD and ASCVD. Two trials supporting hypercholesterolemia and one trial in SHTG have been completed under NCT02722408, NCT02634151 and NCT02944383, respectively.…







